HGH Frag176-191
Price range: $130.00 through $193.00
The synthetic peptides corresponding to amino acids 172-191, 176-191, 177-191, 178-191, 179-191, and 180-191 of human growth hormone (hGH) have been studied for their in vivo effects in normal rats. Four of the peptides (hGH 172-191, 176-191, 177-191, and 178-191) produced a short-lived rise in blood glucose and a more sustained rise in plasma insulin, whereas the other two (hGH 179-191 and 180-191) were inert in the systems tested. A single dose (5 nmol/kg body wt) of the peptides containing the amino acids sequence 178-191 of the hGH molecule significantly reduced insulin sensitivity of the animals in intravenous insulin tolerance tests. The findings also indicate that the biologically active peptides must not only have the minimum of the informational sequence but also that this must be in correct physical configuration.
Description
HGH Fragment 176–191 (also known as hGH Frag 176–191, Frag 176–191, or AOD-9604) is a synthetic peptide derived from the C-terminal end of human growth hormone (hGH). It is primarily studied for its potential effects on fat metabolism and body weight regulation, and is generally intended for research use only, not for human consumption.
Introduction
Numerous drugs with potent toxicity against cancer cells are available for treating malignancies, but therapeutic efficacies are limited due to their inefficient tumor targeting and deleterious effects on non-cancerous tissue. Therefore, two improvements are mandatory for improved chemotherapy 1) novel delivery techniques that can target cancer cells to deliver anticancer drugs and 2) methods to specifically enhance drug efficacy within tumors. The loading of inert drug carriers with anticancer agents and peptides which are able to bind (target) tumor-related proteins to enhance tumor drug accumulation and local cytotoxicity is a most promising approach.
Additional information
| Weight | 500 g |
|---|---|
| Dimensions | 20 × 10 × 8 cm |
| FORMAT | 10Bottlex5mg, 10Bottlex10mg |





